ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
Bu çalışma, CD30 pozitif klasik Hodgkin lenfoma (Hodgkin lymphoma) olan hastalarda ATLCAR.CD30.CCR4 adı verilen özel bağışıklık hücrelerinin (bir hücre tedavisi) kemoterapi ile birlikte verilmesini incelemektedir. Çalışmaya 18 yaş ve üzeri, klasik Hodgkin lenfoma tanısı olan hastalar katılabilmektedir. Faz 1/Faz 2 aşamasında yürütülmekte ve halen katılımcı almaktadır.
Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.
Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.
During the period of cell procurement and lymphodepletion, subjects will be eligible to receive standard-of-care therapy e.g., chemotherapy or radiation therapy to stabilize their disease if the treating physician feels it is in the subject's best interests. Eligibility must be maintained up until the subject is procured, receives lymphodepletion, or receives treatment for the subject to be considered eligible to proceed with the specific phase of the study. Inclusion Criteria: Unless otherwise noted, subjects must meet all of the following criteria to participate in all phases of the study. As these criteria are unchanging they will be evaluated at the time of initial enrollment and not continuously throughout the study. 1. Written informed consent and HIPAA authorization for release of personal health information explained to, understood by, and signed by the subject or legally authorized representative. 2. Age ≥ 18 years at the time of consent. 3. Karnofsky score of \> 60% 4. The subject must have a diagnosis of Classical Hodgkin Lymphoma according to World Health Organization criteria. Exclusion Criteria: 1. Subjects had major surgery within 28 days. 2. Subject received investigational agents or tumor vaccines within 3 weeks. 3. Subject received chemotherapy or radiation therapy within the previous 3 weeks.